BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
BMRN Hot Sheet
Revenue Growth %: +6.5%Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -734K
Today's EPS Names:
UVV, BAMM, TATT, More
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reports Q3 EPS of $0.13, 12 cents better than the analyst estimate of $0.01. Revenue for the quarter was $80.8 million, which compares to the estimate of $82 million.
BioMarin lowers FY09 revenue view to $313-$327 million, versus $324.8 million consensus.
BioMarin lowers FY09 revenue view to $313-$327 million, versus $324.8 million consensus.
You May Also Be Interested In
- UPDATE: Ralph Lauren Corp (RL) Reports Solid Q4 Results; Guides FY13 Sales
- Analog Devices, Inc. (ADI) Tops Q2 EPS by 2c; Guides In-line
- Express (EXPR) Misses Q1 EPS by 2c; Comps Up 4%; Cuts FY12 EPS Outlook, Guides Q2
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
